Cardiovascular responses to the isoprostanes iPF2(α)-III and iPE2-III are mediated via the thromboxane A2 receptor in vivo

Circulation

Volumn 101, Issue 24, 2000, Pages 2833-2840

  Audoly, Laurent P ^a   Rocca, Bianca ^b   Fabre, Jean Etienne ^c   Koller, Beverly H ^c   Thomas, Dennis ^a   Loeb, Alex L ^b   Coffman, Thomas M ^a   FitzGerald, Garret A ^b,d  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Isoprostane; Receptors; Thromboxane

Indexed keywords

ISOPROSTANE DERIVATIVE; THROMBOXANE A2 RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL TONE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; HEART MUSCLE REPERFUSION; LIPID PEROXIDATION; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRESSOR RESPONSE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

EID: 0034691261     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.24.2833     Document Type: Article

References (49)

1. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical catalyzed mechanism. Proc Natl Acad Sci U S A. 1990;87: 9383-9387.
2. Lawson JA, Rokach J, FitzGerald GA. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem. 1999;35: 24441-24444.
3. 2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci U S A. 1992;89:10721-10725.
4. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol. 1997; 17:2309-2315.
5. Liu T, Stern A, Roberts LJ, et al. The isoprostanes: novel prostaglandin-like products of the free radical-catalyzed peroxidation of arachidonic acid. J Biomed Sci. 1999;6:226-235.
6. Narumiya S. Prostanoid receptors and signal transduction. Prog Brain Res. 1996;113:231-241.
7. 2α. J Biol Chem. 1997;272:27147-27154.
8. 2α-III, induce cardiomyocyte hypertrophy: differential activation of downstream signaling pathways. J Biol Chem. 1998;273:22442-22452.
9. 2 receptor. Nature (Lond). 1991;349: 617-620.
10. 2 receptors in human platelets. J Pharmacol Exp Ther. 1994;270:1192-1196.
11. 2α. J Pharmacol Exp Ther. 1997;281:957-964.
12. Leitinger N, Blazek I, Sinzinger H. The influence of isoprostanes on ADP-induced platelet aggregation and cyclic AMP-generation in human platelets. Thromb Res. 1997;86:337-342.
13. 2 receptors. J Clin Invest. 1992;90:136-141.
14. 2α, on the rabbit lung in vivo. Prostaglandins. 1997;53:69-82.
15. 2 isoprostanes are ligands for peroxisome proliferation-activated receptors α and γ. FASEB J. 1999;13:A1549.
16. 2-isoprostane receptors on rat vascular smooth muscle cells. Am J Physiol. 1993;264:C1619-C1624.
17. 2. Am J Physiol. 1997;272:F477-F483.
18. 2 receptor. J Biol Chem. 1995;269:19256-19262.
19. Harats H, Kurihara H, Belloni P, et al. Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter. J Clin Invest. 1995;95:1335-1344.
20. 2. J Clin Invest. 1998;102:1994-2001.
21. Habib A, Vezza R, Creminon C, et al. Rapid agonist-dependent phosphorylation of human thromboxane receptors. J Biol Chem. 1997;272:7191-7210.
22. Rocca B, Loeb AL, Strauss JF III, et al. Directed vascular expression of the thromboxane A2 receptor results in intrauterine growth retardation. Nat Med. 2000;6:219-221.
23. Loeb AL. Pressor response to nitric oxide synthase inhibition during halothane anesthesia in rats is altered by inspired oxygen concentration. Anesthesiology. 1998;88:542-545.
24. 2-isoprostanes formed by free radical oxidation of arachidonic acid. J Am Soc Mass Spectrom. 1996;7:490-499.
25. Morrow JD, Minton TA, Mukundan CR, et al. Free radical-induced generation of isoprostanes in vivo: evidence for the formation of D-ring and E-ring isoprostanes. J Biol Chem. 1994;269:4317-4326.
26. 2-isoprostanes to plaque instability in human carotid atherosclerosis. J Clin Invest. 1999;103:421-424.
27. Chen Y, Morrow JD, Roberts LJ II. Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. J Biol Chem. 1999;274:10863-10868.
28. 2, a product of the isoprostane pathway, in oxidized low density lipoprotein. J Biol Chem. 1999;274:20271-20280.
29. 2 receptor gene. J Biol Chem. 1993;268:25253-25259.
30. Vezza R, Habib A, FitzGerald GA. Differential signaling by the thromboxane receptor isoforms via the novel GTP-binding protein, Gh. J Biol Chem. 1999;274:12774-12779.
31. 2 receptor alpha and beta isoforms: role of the differentially spliced COOH terminus in agonist-promoted receptor internalization. J Biol Chem. 1999; 274:8941-8948.
32. 2 in reocclusion following coronary thrombolysis with tissue type plasminogen activator. Proc Natl Acad Sci U S A. 1989;86:7585-7589.
33. 2α generation during coronary reperfusion: a potential quantitative marker of oxidant stress in vivo. Circulation. 1997;95:2492-2499.
34. 2-isoprostane. Biochem Biophys Res Commun. 1993;195:507-515.
35. 2 receptor (TP) alpha and beta isoforms. Biochim Biophys Acta. 1998;1425:543-559.
36. αq. J Pharmacol Exp Ther. 1996; 277:1132-1139.
37. 2 in human platelets: discrimination of two binding sites linked to distinct effector systems. J Biol Chem. 1990;265: 6836-6844.
38. 2 receptor isoforms in human platelets: opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest. 1996;97: 949-956.
39. Habib A, FitzGerald GA, Maclouf J. Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. J Biol Chem. 1999;274:2645-2651.
40. 2-receptor blockade. Circulation. 1991;84:1568-1580.
41. 2 blockade on clinical outcome and restenosis after successful coronary angioplasty: Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). Circulation. 1995;92:3194-3200.
42. Murata T, Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response in mice lacking the prostacyclin receptor. Nature. 1997;388:678-682.
43. Numaguchi Y, Naruse K, Harada M, et al. Prostacyclin synthase gene transfer accelerates reendothelialization and inhibits neointimal formation in rat carotid arteries after balloon injury. Arterioscler Thromb Vasc Biol. 1999;19:727-733.
44. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96:272-277.
45. Catella-Lawson F, McAdam B, Morrison B, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics and vasoactive eicosanoids. J Pharm Exp Ther. 1999;289:735-741.
46. Ogletree ML. O'Keefe EH, Durham SK, et al. Gastroprotective effects of thromboxane receptor antagonists. J Pharmacol Exp Ther. 1992;263: 374-380.
47. Diener HC, Forbes CC, Sivenius J, et al. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
48. Pratico D, Tangilara KR, Rader DJ, et al. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med. 1998;4:1189-1192.
49. Cayatte AJ, Du Y, Yaghoubi M, et al. The TP-receptor antagonist S218886, but not aspirin, inhibits atherogenesis in ApoE-deficient mice: evidence that other eicosanoids contribute to atherosclerosis. Arterioscler Thromb Vasc Biol. In press.